PL2132204T3 - Postacie krystaliczne związku 8-azabicyklo[3.2.1]oktanu - Google Patents

Postacie krystaliczne związku 8-azabicyklo[3.2.1]oktanu

Info

Publication number
PL2132204T3
PL2132204T3 PL08726162T PL08726162T PL2132204T3 PL 2132204 T3 PL2132204 T3 PL 2132204T3 PL 08726162 T PL08726162 T PL 08726162T PL 08726162 T PL08726162 T PL 08726162T PL 2132204 T3 PL2132204 T3 PL 2132204T3
Authority
PL
Poland
Prior art keywords
azabicyclo
crystalline forms
octane compound
octane
compound
Prior art date
Application number
PL08726162T
Other languages
English (en)
Polish (pl)
Inventor
Sean Dalziel
Leticia M Preza
Miroslav Rapta
Pierre-Jean Colson
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39620376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2132204(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of PL2132204T3 publication Critical patent/PL2132204T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL08726162T 2007-02-28 2008-02-27 Postacie krystaliczne związku 8-azabicyklo[3.2.1]oktanu PL2132204T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90409007P 2007-02-28 2007-02-28
EP08726162A EP2132204B1 (en) 2007-02-28 2008-02-27 Crystalline forms of an 8-azabicyclo[3.2.1]octane compound
PCT/US2008/002583 WO2008106159A1 (en) 2007-02-28 2008-02-27 Crystalline forms of an 8-azabicyclo[3.2.1]octane compound

Publications (1)

Publication Number Publication Date
PL2132204T3 true PL2132204T3 (pl) 2013-06-28

Family

ID=39620376

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08726162T PL2132204T3 (pl) 2007-02-28 2008-02-27 Postacie krystaliczne związku 8-azabicyklo[3.2.1]oktanu

Country Status (26)

Country Link
US (7) US7943772B2 (enExample)
EP (1) EP2132204B1 (enExample)
JP (2) JP5512289B2 (enExample)
KR (1) KR101480530B1 (enExample)
CN (1) CN101616916B (enExample)
AR (2) AR065554A1 (enExample)
AU (1) AU2008219615B2 (enExample)
BR (1) BRPI0807974B8 (enExample)
CA (1) CA2678073C (enExample)
CL (1) CL2008000573A1 (enExample)
CO (1) CO6220856A2 (enExample)
CY (1) CY1115077T1 (enExample)
DK (1) DK2132204T3 (enExample)
ES (1) ES2402031T3 (enExample)
HR (1) HRP20130193T1 (enExample)
IL (1) IL200131A (enExample)
MX (1) MX2009009141A (enExample)
MY (1) MY148318A (enExample)
NZ (1) NZ578871A (enExample)
PL (1) PL2132204T3 (enExample)
PT (1) PT2132204E (enExample)
RU (1) RU2458061C2 (enExample)
SI (1) SI2132204T1 (enExample)
TW (1) TWI409067B (enExample)
WO (1) WO2008106159A1 (enExample)
ZA (1) ZA200905832B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY145633A (en) 2006-03-01 2012-03-15 Theravance Inc 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
TWI409067B (zh) * 2007-02-28 2013-09-21 Theravance Inc 8-氮雜雙環〔3.2.1〕辛烷化合物之結晶型
TWI415850B (zh) * 2007-07-20 2013-11-21 Theravance Inc 製備mu類鴉片受體拮抗劑之中間物的方法
WO2009029253A1 (en) * 2007-08-27 2009-03-05 Theravance, Inc. Heteroarylalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
DE602008005771D1 (de) * 2007-08-27 2011-05-05 Theravance Inc Disubstituierte alkyl-8-azabicycloä3.2.1üoktan-verbindungen als mu-opioid-rezeptorantagonisten
TWI423801B (zh) * 2007-08-27 2014-01-21 Theravance Inc 作為μ類鴉片受體拮抗劑之8-氮雜雙環〔3.2.1〕辛基-2-羥基苯甲醯胺化合物
EP2185553B1 (en) * 2007-08-27 2012-06-27 Theravance, Inc. Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
JP5797655B2 (ja) * 2009-09-18 2015-10-21 アドラー・コーポレーション 消化管障害のためのオピオイド受容体アンタゴニストの使用
HRP20200432T1 (hr) 2015-04-02 2020-06-12 Theravance Biopharma R&D Ip, Llc Oblik za kombinacijsko doziranje antagonista mu opioidnog receptora i opioidnog sredstva

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5159081A (en) 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
US6900228B1 (en) 1998-03-10 2005-05-31 Research Triangle Institute Opiate compounds, methods of making and methods of use
GB9810671D0 (en) 1998-05-18 1998-07-15 Pfizer Ltd Anti-pruritic agents
TWI244481B (en) 1998-12-23 2005-12-01 Pfizer 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
GB9912410D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
US6469030B2 (en) 1999-11-29 2002-10-22 Adolor Corporation Methods for the treatment and prevention of ileus
US6467084B1 (en) * 1999-12-16 2002-10-15 Emware, Inc. Systems and methods for reprogramming an embedded device with program code using relocatable program code
US6552036B2 (en) 2000-03-03 2003-04-22 Ortho-Mcneil Pharmaceutical, Inc. 3-(Diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives
US20020025948A1 (en) 2000-06-23 2002-02-28 Banks Bernard Joseph 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
AP1816A (en) 2001-10-22 2008-01-04 Pfizer Prod Inc 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists.
US7381721B2 (en) 2003-03-17 2008-06-03 Adolor Corporation Substituted piperidine compounds
US20040204453A1 (en) 2003-04-14 2004-10-14 Pfizer Inc 4-Phenyl-piperidine compounds and their use as modulators of opioid receptors
MXPA05011070A (es) 2003-04-14 2005-12-12 Pfizer Prod Inc Derivados de 3-azabiciclo [3.2.1] octano.
US7056930B2 (en) * 2003-04-14 2006-06-06 Pfizer Inc. 2-Azabicyclo[3.3.1]nonane derivatives
JP2006523673A (ja) 2003-04-15 2006-10-19 ファイザー・プロダクツ・インク オピオイド受容体活性を有する3−ベンズヒドリリデン−8−アザ−ビシクロ[3.2.1]オクタン誘導体
US6992090B2 (en) 2003-06-16 2006-01-31 Adolor Corporation Substituted piperidine compounds and methods of their use
EP1737853A1 (en) 2004-02-03 2007-01-03 Janssen Pharmaceutica N.V. 3-(diheteroarylmethylene)-8-azabicyclo¬3.2.1|octane and 3-((aryl)(heteroaryl)methylene)-8-azabicyclo¬3.2.1|octane derivatives
US7087749B2 (en) 2004-03-11 2006-08-08 Adolor Corporation Substituted piperidine compounds and methods of their use
MY145633A (en) 2006-03-01 2012-03-15 Theravance Inc 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
CN101534827A (zh) 2006-11-07 2009-09-16 尼克塔治疗亚拉巴马公司 阿片样物质激动剂和阿片样物质拮抗剂的剂型和联合给药
TWI409067B (zh) * 2007-02-28 2013-09-21 Theravance Inc 8-氮雜雙環〔3.2.1〕辛烷化合物之結晶型

Also Published As

Publication number Publication date
AU2008219615B2 (en) 2013-05-09
JP2013151564A (ja) 2013-08-08
US20160287572A1 (en) 2016-10-06
US8247555B2 (en) 2012-08-21
US20130072515A1 (en) 2013-03-21
US20150073014A1 (en) 2015-03-12
US9949963B2 (en) 2018-04-24
MX2009009141A (es) 2009-09-03
US20110184008A1 (en) 2011-07-28
SI2132204T1 (sl) 2013-05-31
US20140080856A1 (en) 2014-03-20
PT2132204E (pt) 2013-03-25
KR20090115767A (ko) 2009-11-05
CA2678073A1 (en) 2008-09-04
IL200131A0 (en) 2010-04-15
BRPI0807974A2 (pt) 2014-09-16
US8536335B2 (en) 2013-09-17
HRP20130193T1 (hr) 2013-03-31
NZ578871A (en) 2012-01-12
WO2008106159A1 (en) 2008-09-04
US8816091B2 (en) 2014-08-26
CL2008000573A1 (es) 2008-05-16
KR101480530B1 (ko) 2015-01-08
MY148318A (en) 2013-03-29
JP5512289B2 (ja) 2014-06-04
TW200845984A (en) 2008-12-01
AR109224A2 (es) 2018-11-07
US9290491B2 (en) 2016-03-22
EP2132204B1 (en) 2013-01-23
CN101616916B (zh) 2011-10-12
IL200131A (en) 2013-03-24
US20180200246A1 (en) 2018-07-19
RU2458061C2 (ru) 2012-08-10
US7943772B2 (en) 2011-05-17
BRPI0807974B1 (pt) 2020-11-24
DK2132204T3 (da) 2013-04-29
ZA200905832B (en) 2010-05-26
TWI409067B (zh) 2013-09-21
RU2009135834A (ru) 2011-04-10
ES2402031T3 (es) 2013-04-26
HK1139399A1 (en) 2010-09-17
CY1115077T1 (el) 2016-12-14
CO6220856A2 (es) 2010-11-19
JP2010520198A (ja) 2010-06-10
US10426766B2 (en) 2019-10-01
EP2132204A1 (en) 2009-12-16
US20080207676A1 (en) 2008-08-28
BRPI0807974B8 (pt) 2021-05-25
AR065554A1 (es) 2009-06-17
AU2008219615A1 (en) 2008-09-04
CA2678073C (en) 2016-01-05
CN101616916A (zh) 2009-12-30

Similar Documents

Publication Publication Date Title
ZA201306383B (en) Crystalline anti-htnfalpha antibodies
ZA200905832B (en) Crystalline forms of an 8-azabicyclo [3.2.1] octane compound
ZA201001434B (en) 2-aza-bicyclo[3.3.0]octane derivatives
EP2181992B8 (en) Polycyclic compound
IL193690A0 (en) 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
ZA200903294B (en) Synthetic cork compound
EP2500345A4 (en) 8-azabicyclo [3.2.1-] octan-8-carboxamide
IL196722A0 (en) Crystalline antifungal compounds
ZA200904423B (en) Crystalline forms GLYT 1
ZA200903614B (en) New crystalline forms
IL177762A0 (en) Bimatoprost crystalline form i
EP3825306B8 (en) Morphinan compounds
ZA200806859B (en) Novel crystalline compounds
IL206032A0 (en) Stable crystalline salt of (r)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabiciyclo [2.2.2]oct-3-yl ester
IL193025A0 (en) Crystalline forms of ciclesonide
IL195092A0 (en) Crystalline form of (s)-1-phenylethylammonium (r)-diphenyl-methanesulphinyl-acetate
ZA200807467B (en) 8-Azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
EP1951257A4 (en) CRYSTALLINE FORMS
HK1135699A (en) New crystalline forms
HK1127344A (en) Crystalline antifungal compounds
HK1144943A (en) Crystalline indazole-derived chemotherepeutic
AU2008902384A0 (en) Dura Feeder
HK1164864A (en) Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750
AU2009252307B2 (en) Heterocyclic compound
HK1119976A (en) Crystalline forms